The global market for Clostridium difficle infection therapeutics is projected to quadruple within the next 10 years. The research and consulting firm GlobalData‘s latest report estimates that the market will increase from $356.3 million in 2014 to $1.5 billion by 2024. They anticipate that Merck’s Dificid will be in the lead for C. diff, and potentially joined by other competitor’s drugs and vaccines currently in the pipeline.
C. difficile caused nearly half a million infections in the U.S. in 2011, and 29,000 of those infected died within 30 days of their diagnosis. Those who take antibiotics and receive medical care are the most at risk, especially the elderly. With C. diff becoming increasingly difficult to treat, it is crucial for new treatments and preventative measures to become available.
Global Clostridium difficile infections market to hit $1.5b by 2024
